title: Antithrombotic strategies in gene therapy.
abstract: Advances in the field of molecular medicine are making gene therapy a viable treatment strategy for the next millennium. Indeed, over the past 10 years, a number of improvements have occurred that have resulted in an increased interest in gene therapy for the treatment of diseases in cardiovascular medicine. Because antithrombotic and anticoagulation therapy generally involves the systemic administration of agents that target a small region of the vasculature, localized and controlled delivery of specific genes could offer enormous potential to treat a number of life-threatening diseases. In addition, gene therapy may allow sustained antithrombotic or anticoagulant treatment when prolonged systemic administration is undesirable. Gene therapy for antithrombotic strategies can involve a number of different approaches. This could include inhibition of coagulation factors, over-expression of anticoagulant factors, or modulation of endothelial biology to make thrombus formation or propagation unfavorable. Preclinical data regarding these different strategies are reviewed and their potential limitations discussed.
authors.affiliation: Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.
authors.forename: K M
authors.initials: KM
authors.lastname: Channon
authors.forename: B H
authors.initials: BH
authors.lastname: Annex
mesh_terms: D000818:Animals; D003328:Coronary Thrombosis / Q000517:prevention & control / Q000628:therapy; D016228:Endothelial Growth Factors / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000473:pathology; D015316:Genetic Therapy; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000235:genetics; D020033:Protein Isoforms / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020246:Venous Thrombosis / Q000517:prevention & control / Q000628:therapy
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D019001:Nitric Oxide Synthase